

Ambulatory Blood Pressure in ONTARGET

Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)

Giuseppe Mancia, Gianfranco Parati, Grzegorz Bilo, Peggy Gao, Robert Fagard, Josep Redon, Istvan Czuriga, Martin Polák, José M. Ribeiro, Ramiro Sanchez, Bruno Trimarco, Paolo Verdecchia, Walter van Mieghem, Koon Teo, Peter Sleight, Salim Yusuf

Abstract—In the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, telmisartan (T; 80 mg daily) and ramipril (R; 10 mg daily) caused similar clinic blood pressure (BP) reductions, with a similar incidence of cardiovascular and renal events. The R+T combination lowered clinic BP somewhat more with no further cardiovascular or renal protection. The aim of this substudy was to see whether these clinic BP changes reflected the changes of 24-hour BP, a BP with a better prognostic value. In 422 patients in whom 24-hour BP monitoring was performed either before or after 6 to 24 months of treatment, demographic and clinical characteristics were similar in the 3 treated groups. Twenty-four-hour systolic BP was similarly reduced by R (−2.0 mmHg) and T (−2.1 mmHg), whereas the reduction was more than twice as large in the T+R group (−5.3 mmHg), which showed a lower on-treatment 24-hour BP also in additional patients (n=408) in whom ambulatory BP was performed only on-treatment. Twenty-four-hour systolic BP was ≈14 mmHg lower than clinic systolic BP at baseline, whereas during treatment the 2 values became progressively closer as clinic systolic BP was more tightly controlled and superimposable when clinic systolic BP was <120 mmHg. Similar results were obtained for diastolic BP. These findings provide evidence on the relationship of clinic and ambulatory BP target drug treatment. They also show that in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, failure of the R+T combination to enhance cardiovascular and renal protection was not because of inability to more effectively control daily life BP. (*Hypertension*. 2012;60:1400-1406.)

Key Words: ambulatory blood pressure ■ antihypertensive treatment ■ high cardiovascular risk
■ angiotensin-converting enzyme inhibitors ■ angiotensin receptor blockers

The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)¹ has shown that in patients at high cardiovascular (CV) risk a treatment regimen based on telmisartan or ramipril reduced to a similar degree clinic blood pressure (BP) and showed no significant difference in the incidence of CV morbid or fatal events. Clinic BP was reduced to a somewhat greater degree in patients treated with a combination of the 2 drugs (1.5–2.4 mmHg systolic BP [SBP] and 0.8–1.4 mmHg diastolic BP [DBP]), without, however, any significant difference in CV outcome. Because ramipril had been shown previously to reduce outcomes in high CV risk individuals²; this led to the conclusion that telmisartan and ramipril have a similar protective effect, which is not enhanced by double blockade of the renin-angiotensin system, despite the potentially greater protection associated with a greater BP-lowering effect.³

Evidence is available that BP reductions induced by antihypertensive treatment cannot be precisely quantified if BP

is measured in the clinic environment because clinic BP is affected to a variable degree by a transient increase known as the white coat effect.⁴ Furthermore, clinic BP values are poorly reproducible,^{5,6} and their treatment-induced changes reflect to only a modest degree the concomitant changes in daily life BP,^{7–10} that is, a more reproducible⁵ and prognostically important BP, which relates more steeply to CV morbidity and mortality.^{11–17}

The ONTARGET included a prespecified substudy¹⁸ focusing on ambulatory BP (ABP) to determine whether and to what extent treatment-induced changes in clinic BP correspond to daily life ABP. This article reports the results.

Methods

Patients and Monitoring Procedures

The protocol of the ONTARGET has been described in detail previously.¹⁸ Briefly, men and women aged ≥55 years without symptomatic heart failure at entry and with a history of coronary

Received May 31, 2012; first decision June 18, 2012; revision accepted August 31, 2012.

From the Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy (M.G., P.G.); Istituto Auxologico Italiano, Milan, Italy (M.G., P.G., B.G.); Population Health Research Institute, Hamilton, Ontario, Canada (G.P., T.K., Y.S.); University of Leuven, Leuven, Belgium (F.R.); University of Valencia, Valencia, Spain (R.J.); University of Debrecen, Debrecen, Hungary (C.I.); Medeurop, Praha, Czech Republic (P.M.); Department of Cardiology, Felicio Rocho Hospital, Belo Horizonte, Brazil (R.J.M.); Fundacion Favaloro, Hospital Universitario, Buenos Aires, Argentina (S.R.); Università di Napoli Federico II, Napoli, Italia (T.B.); Ospedale di Assisi, Perugia, Italia (V.P.); Ziekenhuis Oost-Limburg, Genk, Belgium (v.M.W.); University of Oxford, Oxford, United Kingdom (S.P.).

This article was sent to Robert M. Carey, Consulting editor, for review by expert referees, editorial decision, and final disposition.

Correspondence to Giuseppe Mancia, Clinica Medica, Ospedale San Gerardo, via Pergolesi 33, 20052 Monza, Italy. E-mail giuseppe.mancia@unimib.it
© 2012 American Heart Association, Inc.

Hypertension is available at <http://hyper.ahajournals.org>

DOI:10.1161/HYPERTENSIONAHA.112.199562

Downloaded from <http://hyper.ahajournals.org/> by guest on February 10, 2016

disease, peripheral artery disease, cerebrovascular disease, or diabetes mellitus complicated by organ damage, were randomly assigned to ramipril (5 mg and then 10 mg QD), telmisartan (80 mg QD), or their combination. The drugs were administered on top of preexisting treatment after a run-in period of 11 to 18 days during which reduced doses of either drug were given to exclude patients intolerant to the study medications. One month after randomization and every 6 months thereafter, 25 620 patients from 733 centers in 40 countries were randomized and evaluated at baseline. The median follow-up period was 4.7 years. The primary end point was a composite of CV death, myocardial infarction, stroke, or hospitalization for heart failure (first occurrence).

The ABP monitoring substudy involved 33 centers from 9 countries (Argentina, Australia, Belgium, Brazil, France, Hungary, Italy, South Africa, and Spain). Centers participated on a voluntary basis, and patients undergoing ABP monitoring were not randomized. Patients underwent a 24-hour (h) ABP monitoring before the run-in period (baseline) and then between 6 and 24 months after randomization, that is, when drug titration had long been completed and therapy was stable. Because this ABP study was initiated after the main study had started, we also included individuals with only on-treatment 24-hour ABP monitoring, which allowed comparison of ABP values under the 3 drug regimens in a larger number of patients. ABP monitoring was performed with a variety of oscillometric devices (Spacelabs, TM 2430 and Meditech), all validated according to international protocols^{19,20} and programmed to measure BP every 15 minutes during

the day (6:00 AM to 12:00 AM) and every 20 minutes during the night (12:00 AM to 6:00 AM). The monitoring cuff was applied around the nondominant arm, usually in the morning, before intake of the study drug(s). Patients were then sent home and instructed to lead a normal life but to keep the arm extended and immobile during the cuff inflation. They were also instructed to record the times of the main daily activities (meals, sleep, etc), to note unusual events, and to come back the following day for the device removal.

Data Analysis

ABP monitoring data were sent to a reading center (Istituto Auxologico Italiano, Milan, Italy) where they were checked for quality. Data were regarded as suitable for further analysis if they met several prespecified criteria, as adopted by international guidelines,²¹ namely the following: (1) the recording lasted ≥ 24 hours; (2) $\geq 70\%$ of the expected number of readings was available; (3) there was ≥ 1 valid measurement per hour. Single measurements were regarded as valid as follows: (1) if SBP was not >300 mmHg or <50 mmHg; (2) if DBP was not >150 mmHg or <40 mmHg; (3) if heart rate was not >150 /min or <40 /min; (4) if pulse pressure (difference between SBP and DBP) was >0 and not >150 mmHg. In the overall population, the average number of valid readings was 82 ± 13 , that is, 91% of the expected number of readings ($n=90$) for 24-hour, daytime, nighttime, and hourly SBP, DBP, and heart rate means were obtained from each ABP recording. Baseline, on-treatment, and changes from baseline values were calculated separately for the 3 treatment groups. We calculated the on-treatment SBP

Table 1. Demographic, Clinical, and Laboratory Characteristics of Patients Who Had an Ambulatory BP Monitoring Either at Baseline and Between 6 and 24 Months After Randomization to Treatment

Demographic/Clinical Variables	ONTARGET, ABPM (n=25 498)	Overall, ABPM (n=422)	Telmisartan, ABPM (n=139)	Ramipril, ABPM (n=142)	Combination, ABPM (n=141)	Overall ABPM <i>P</i> Value
Female, %	26.7	24.6	24.5	28.2	21.3	0.404
Age, y	66.4 (7.2)*	65.6 (6.9)	66.1 (7.2)	66.2 (6.7)	64.6 (6.6)	0.091
White, %	73.0*	87.7	87.1	88.7	87.2	0.895
Hypertension, %	68.7*	57.1	53.2	62.7	55.3	0.243
Diabetes mellitus, %	37.5*	30.1	27.3	26.8	36.2	0.155
Current smoking, %	12.6	10.7	9.4	12.0	10.6	0.776
Angina, %	44.9	44.5	41.7	48.6	43.3	0.477
CAD, %	74.6*	68.7	66.9	72.5	66.7	0.484
PAD, %	13.5	15.6	15.8	14.8	16.3	0.937
Stroke/TIA, %	20.9	18.0	18.7	18.3	17.0	0.929
CABG or PTCA, %	46.1	45.7	47.5	47.2	42.6	0.648
β -Blockers, %	56.9	54.5	47.5	57.0	58.9	0.122
Calcium antagonists, %	33.1	37.0	38.8	32.4	39.7	0.378
Diuretics, %	28.0	28.0	21.6	31.7	30.5	0.120
Angiotensin II antagonists, %	8.6	9.2	8.6	9.9	9.3	0.939
Statins, %	61.6*	48.3	38.8	49.3	56.7	0.011
ASA, %	75.7*	67.3	64.0	72.5	65.2	0.257
ACE inhibitors, %	57.6	60.2	53.2	59.9	67.4	0.054
Ankle-arm BP ratio	1.1 (0.2)	1.1 (0.2)	1.1 (0.2)	1.1 (0.2)	1.1 (0.1)	0.873
Body mass index, kg/m ²	28.1 (4.5)	28.1 (3.8)	28.0 (3.9)	28.4 (3.9)	28.1 (3.5)	0.646
Waist-hip ratio	0.94 (0.08)	0.95 (0.08)	0.95 (0.08)	0.94 (0.08)	0.94 (0.07)	0.317
Serum creatinine, mmol/L	94.2 (24.3)	93.7 (22.7)	90.5 (19.8)	96.3 (24.7)	94.4 (23.2)	0.095
Serum glucose, mmol/L	6.7 (2.6)	6.4 (2.2)	6.3 (2.1)	6.4 (2.3)	6.5 (2.2)	0.653
Serum cholesterol, mmol/L	5.0 (1.1)	5.1 (0.9)	5.2 (1.0)	5.1 (1.0)	5.0 (0.9)	0.119

ONTARGET indicates Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial; ABPM, ambulatory blood pressure monitoring; CAD, coronary artery disease; PAD, peripheral artery disease; TIA, transient ischemic attack; CABG, coronary artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty; ASA, antiplatelet drugs; ACE, angiotensin-converting enzyme. Data are shown as % or mean \pm SD (in parenthesis). Drugs refer to use before the run-in period. Baseline characteristics of all ONTARGET patients (except the 422 involved in the substudy) are also shown for comparison.

* $P < 0.03$ from overall ambulatory BP group.

and DBP smoothness indices,^{22,23} which were obtained by the ratio between the mean and the SD of the hourly BP changes induced by treatment. This provided a normalized measure of the homogeneity of BP reduction throughout the 24 hours, which has been shown to have a normal distribution, a high reproducibility, and an independent relationship with left ventricular mass and carotid intima-media thickness.^{22,23} ABP values were compared with clinic BP values (mean of 2 measurements in the sitting position 3 months apart) obtained by a semiautomatic device (OMRON, model HEM-757)¹⁸ at the visit when ABP monitoring was started. Between-group comparisons were made by unpaired (different treatments) or paired (treatment versus pretreatment) *t* tests. *P* values for the BP changes induced by treatment were calculated after adjustment for baseline BP. The *t* tests were 2 sided and the Tukey method was used for multiple comparisons. Data from the different groups were pooled to calculate clinic-ABP differences at baseline and during treatment according to the target clinic SBP values recommended by guidelines or used in trials on high CV risk patients.^{24,25} Pooled data were also used to calculate the correlations between clinic BP and ABP or daytime and nighttime BP values before and during treatment. A *P*<0.05 was taken as the level of statistical significance. Data are shown as mean±SD or 95% CIs.

Results

BP Changes With Treatment

ABP monitoring was performed in 422 patients either at baseline or after 6 or 24 months of treatment. Table 1 shows that demographic and clinical characteristics at baseline were comparable in the 3 treated groups. This was also the case for baseline clinic and 24-hour SBP and DBP, which were much lower than clinic SBP and DBP. Additionally, SBP and DBP values were much less during the night when compared with daytime (Figure 1). This was the case also for heart rate whose 24 hour values were similar to clinic values with no between-group differences. As shown in Figure 2, in these 422 patients treatment, significantly reduced 24-hour SBP and DBP from the pretreatment values. The reduction was similar in the telmisartan and ramipril groups but significantly and markedly greater in the group under combination treatment, which also showed SBP and DBP smoothness index values that were

almost twice as large as those seen in the monotherapy group (Figure 3). In all 3 groups, BP reduction induced by treatment was greater for clinic BP than for ABP, for the day than for the night (during which the BP reduction was small and often not significant) and for SBP than for DBP.

Absolute On-Treatment SBP and DBP

A total of 830 patients had 1 ABP monitoring between 6 and 24 months after initiation of treatment. As shown in Table 2, clinic SBP was similar, whereas ambulatory SBP was lower in the telmisartan than in the ramipril group, the mean difference achieving statistical significance for 24-hour (−3.1 mmHg) and nighttime (−4.1 mmHg) values. Compared with patients on monotherapy, clinic and ambulatory SBP were lower in the group under combination treatment (Table 2 and Figure 4) although the mean differences were statistically significant mainly versus patients on ramipril (24-hour, −4.4 mmHg; daytime, −4.8 mmHg; nighttime, −3.8 mmHg). On-treatment DBP displayed much smaller or no between-group differences, this being the case also for on-treatment heart rate (data not shown).

Correlations and Differences Between Baseline and On-Treatment Clinic and ABP

In the 422 patients in whom baseline and on-treatment values were available, correlations between clinic and 24-hour BP values were significant but not close either for SBP (correlation coefficient 0.39 and 0.58 at baseline and during treatment, respectively; *P*<0.0001 for both) or for DBP (correlation coefficient 0.51 and 0.49; *P*<0.0001 for both). Treatment-induced changes of clinic and 24-hour SBP and DBP were even less closely related (0.33 and 0.24, respectively; *P*<0.0001 for both). Figure 5 shows that in all available patients the marked differences between clinic and 24-hour or daytime SBP and DBP seen at baseline became progressively smaller in patients achieving a progressively lower target clinic SBP with treatment and that the 2 sets of values were substantially similar in the group in which clinic SBP was reduced to <120 mmHg.




Figure 1. Baseline clinic and ambulatory systolic blood pressure (SBP) and diastolic blood pressure (DBP) in 422 patients treated with ramipril (R), telmisartan (T), or their combination (R+T) in whom a 24-hour ambulatory BP was performed either before or during treatment (see Methods). Data are shown as mean±SD values. Baseline heart rate (HR) values are reported at the bottom of each panel. No between-group difference was statistically significant.




Figure 2. Changes in clinic and ambulatory systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline after 6 to 24 months of treatment with ramipril (R), telmisartan (T), or their combination (R+T) in the 422 patients of Figure 1. P values refer to changes from baseline or between-group, after adjustment for baseline values. No P values means no statistical significance.

Discussion

Our study shows that in the ONTARGET patients of the ABP substudy, telmisartan caused a similar or only slightly greater reduction of ABP than ramipril. It also shows that the reduction was much more pronounced in patients under combination with the 2 drugs in whom the BP-lowering effect was at least twice as large as that associated with one or the other monotherapy throughout the day and night. This rules out the possibility that in ONTARGET the ramipril-telmisartan combination did not lead to a greater CV or renal protection^{1,26} because of a limited effect on daily life BP, a variable of important prognostic significance. On the contrary, the combination lowered daily life BP even more clearly than could be inferred from clinic BP measurements, with also a greater smoothness index and thus a greater between-hour consistency of the antihypertensive effect and a lower BP variability, a parameter that has been shown to have independent prognostic significance.²⁷⁻³⁰ This implies that other explanations should be sought for the failure of the combination to improve CV or renal outcome

compared with the combination components in monotherapy. We can speculate that at the doses used in ONTARGET, double blockade of the renin-angiotensin system had direct harmful effects that neutralized the protection associated with the greater ABP reduction. It is also possible, however, that because initial ABP values were largely within the normal range^{24,31} their relationship with events was flatter than at higher values, with thus no substantial effect of greater or smaller treatment-induced changes. We cannot exclude that larger ABP reductions from initially normal values had a detrimental effect, a J curve-like phenomenon³² that masked a greater benefit of the more complete blockade of the renin-angiotensin system provided by the combination.

An interesting additional finding of our study is that while in baseline conditions ABP values were markedly lower than the clinic ones, the difference was less during treatment and more so as clinic BP achieved a progressively lower target. Indeed, when the target was set at <130 mmHg (the value recommended by guidelines for high CV risk individuals such as those from ONTARGET),²⁴ daytime ABP was <1 mmHg lower than clinic BP and day and 24-hour BP values were superimposable with clinic BP in patients in whom the clinic BP target was <120 mmHg, that is, the value aimed at in the more intensively treated high CV risk patients of the action to control cardiovascular risk in diabetes mellitus study.²⁵ The reasons for this decreasing clinic-ABP difference from baseline to progressively more aggressive treatments are not explained by our study, although we can speculate that several factors (eg, regression dilution, waning of the white coat effect, and resistance to treatment of daily life BP) may be involved. The results, however, are relevant to the debated question of which ABP values should be recommended for treatment, an issue on which there is no direct evidence because no event-based trial has so far systematically measured ABP before and at various times during treatment.³³ In this context, our study suggests that daytime or 24-hour BP targets for treatment may not be too different from the clinic ones, particularly when, as in patients at high CV risk, a tighter clinic BP control is pursued.




Figure 3. Smoothness index values in patients of Figure 1. SBP indicates systolic blood pressure; DBP, diastolic blood pressure; R, ramipril; T, telmisartan.

Table 2. Clinic and Ambulatory Blood Pressure Mean Values and SDs (in Brackets) in the 3 Treatment Groups After 6 to 24 Months of Treatment (n=830)

Clinic SBP and DBP	Telmisartan	Ramipril	Combination	Overall <i>P</i>
n	275	284	271	
Clinic SBP, mm Hg	135.5 (16.0)†	136.3 (16.6)‡	131.9 (16.7)*	0.005
Clinic DBP, mm Hg	77.1 (9.9)	78.4 (10.1)	76.6 (10.5)	0.080
24-h SBP, mm Hg	124.0 (14.8)	127.1 (14.9)*‡	122.7 (16.1)	0.003
24-h DBP, mm Hg	70.8 (8.0)	71.9 (8.9)	70.6 (9.2)	0.162
Daytime SBP, mm Hg	126.0 (15.4)	128.5 (14.7)‡	123.7 (16.5)	0.001
Daytime DBP, mm Hg	72.9 (8.7)	74.0 (9.2)	72.4 (9.6)	0.099
Nighttime SBP, mm Hg	117.6 (16.4)	121.7 (18.3)*†	117.9 (18.8)	0.011
Nighttime DBP, mm Hg	65.3 (8.7)	66.6 (10.3)	65.6 (10.4)	0.267

SBP indicates systolic blood pressure; DBP, diastolic blood pressure.

**P*<0.05 vs telmisartan.

†*P*<0.05.

‡*P*<0.01 vs combination.

Several other results of our study are noteworthy. First, in the ONTARGET patients, the ambulatory SBP reductions induced by telmisartan, ramipril, and the combination of the 2 drugs were all greater than the 24-hour DBP reductions, which means that the BP-lowering effect includes a reduction of pulse pressure. Because in elderly patients like those of ONTARGET pulse pressure has prognostic significance,^{34,35} this can be regarded as a potentially favorable effect common to all treatments used. In line with the results of previous studies,³⁶ daytime BP was reduced by treatment more than nighttime BP on which the effect was usually so small as to make differences from baseline values not statistically significant. This may have occurred because the drugs were given in the morning, which made their concentration in blood and tissues lower at night. It may also be explained, however, by the law of initial value, that is, irrespective of the treatment used, the magnitude of a BP reduction is directly related to the initial BP value, which is much lower during the night than during the day. Clinic BP and ABP values were significantly related to each other, but the correlation coefficients were low. This was even more the case for their treatment-induced changes, which confirms previous evidence that individual patient measurements made in the clinic environment do not provide an accurate assessment of daily life BP, including its

modification by treatment.⁷⁻¹⁰ This represents an additional argument in favor of an extensive use of ABP in future trials of the beneficial effects of antihypertensive drugs.

Our study has strengths and limitations. An important strength is that BP data were carefully checked for quality, which led to the inclusion in the data analysis of only ABP with adequate data. An important limitation, on the other hand, is that, as in all previous ABP data collected in trials, ABP data were collected from nonrandomized patients who were a small fraction of the overall ONTARGET population. This raises the question of whether the present findings are representative of those of the ONTARGET as a whole. Although remaining unproven, we suggest that this may be the case, because most baseline demographic and clinical characteristics of the patients did not differ significantly from those reported in the main study (Table 1). Furthermore, in the overall ONTARGET patients, the clinic BP values at run-in (141.8/82.1 mmHg) were not substantially different from those of the ABP monitoring patients. This was the case also for the BP reductions between 6 and 24 months of treatment which in all ONTARGET patients were on average 5.4/4.4, 4.4/3.3, and 7.8/4.9 mmHg for the telmisartan, ramipril, or their combination groups, respectively.




Figure 4. Hourly systolic blood pressure (SBP) and diastolic blood pressure (DBP) profiles in 830 patients under treatment with ramipril (R), telmisartan (T), or their combination (R+T) for 6 to 24 months. Data are shown as hourly mean values.




Figure 5. Absolute clinic and 24-hour blood pressure (BP) values (top) and differences at baseline and at different BP targets with treatment. Data are from all available patients. SBP indicates systolic blood pressure; S, systolic; D, diastolic.

Perspectives

The ONTARGET ABP monitoring substudy shows that the telmisartan/ramipril combination induced a substantially greater ABP reduction compared with telmisartan or ramipril alone. This rules out the possibility that the combination did not protect patients more than the monotherapies because it failed to more effectively control a variable of important prognostic significance, such as daily life BP. Furthermore, our data confirm that, in individual patients, significant discrepancies exist between the information offered by clinic BP and ABP monitoring both at baseline and during treatment, which emphasizes the need to obtain systematic information on daily life BP in outcome trials. Finally, our data shed light on the quantitative relationship between clinic BP and ABP before and during treatment. The main finding is that, whereas before treatment ABP is much lower than clinic BP, the 2 sets of values come closer during treatment and are similar in patients under stricter clinic BP control. This is relevant to the debated question of what should be the ABP target.

Disclosures

Giuseppe Mancia, Gianfranco Parati, Robert Fagard, Josep Redon, Paolo Verdecchia, Koon Teo, and Salim Yusuf received consulting, lecture fees, and research grants from Boehringer Ingelheim and from other companies manufacturing angiotensin receptor blockers. The other authors have no conflicts to report.

References

1. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med.* 2008;358:1547–1559.
2. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. *N Engl J Med.* 2000;342:145–153.
3. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *The Lancet.* 2003;362:1527–1535.
4. Mancia G, Bertinieri G, Grassi G, Parati G, Pomidossi G, Ferrari A, Gregorini L, Zanchetti A. Effects of blood-pressure measurement by the doctor on patient's blood pressure and heart rate. *Lancet.* 1983;2:695–698.
5. Trazzi S, Mutti E, Frattola A, Imholz B, Parati G, Mancia G. Reproducibility of non-invasive and intra-arterial blood pressure monitoring: implications for studies on antihypertensive treatment. *J Hypertens.* 1991;9:115–119.
6. Conway J, Johnston J, Coats A, Somers V, Sleight P. The use of ambulatory blood pressure monitoring to improve the accuracy and reduce the numbers of subjects in clinical trials of antihypertensive agents. *J Hypertens.* 1988;6:111–116.
7. Mancia G, Omboni S, Parati G; Investigators of the INSIGHT ABPM Substudy. Twenty-four hour ambulatory blood pressure in the International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT). *J Hypertens.* 2002;20:545–553.
8. Mancia G, Parati G, Bilo G, Choi J, Kilama MO, Ruilope LM; TALENT Investigators. Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TALENT study. *J Hypertens.* 2011;29:600–609.
9. Mancia G, Omboni S, Parati G, Clement DL, Haley WE, Rahman SN, Hoogma RP. Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. *J Hypertens.* 2001;19:1755–1763.
10. Mancia G, Parati G, Bilo G, Maronati A, Omboni S, Baurecht H, Hennig M, Zanchetti A. Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. *J Hypertens.* 2007;25:1087–1094.
11. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension: Systolic Hypertension in Europe Trial Investigators. *JAMA.* 1999;282:539–546.
12. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, Mancia G. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. *Circulation.* 2005;111:1777–1783.
13. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. *Hypertension.* 2005;46:156–161.

14. Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension: a 10-year follow-up study. *Circulation*. 1998;98:1892–1897.
15. Kikuya M, Hansen TW, Thijs L, Björklund-Bodegård K, Kuznetsova T, Ohkubo T, Richart T, Torp-Pedersen C, Lind L, Ibsen H, Imai Y, Staessen JA; International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes Investigators. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. *Circulation*. 2007;115:2145–2152.
16. Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, Gheeraert PJ, Missault LH, Braun JJ, Six RO, Van Der Niepen P, O'Brien E; Office Versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. *N Engl J Med*. 2003;348:2407–2415.
17. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. *J Hypertens*. 2007;25:2193–2198.
18. The ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. *Am Heart J*. 2004;148:52–61.
19. O'Brien E, Petrie J, Littler WA, de Swiet M, Padfield PL, Altman D, Bland M, Coats A, Atkins N. The British Hypertension Society Protocol for the evaluation of blood pressure measuring devices. *J Hypertens*. 1993;11:S43–S63.
20. Association for the Advancement of Medical Instrumentation. *American National Standard. Manual, Electronic or Automated Sphygmomanometers ANSI/AAMI SP10-2002*. Arlington, VA: AAMI; 2003.
21. Omboni S, Costantini C, Pini C, Bulegato R, Manfellotto D, Rizzoni D, Palatini P, O'Brien E, Parati G. PA.NET International Quality Certification Protocol for blood pressure monitors. *Blood Press Monit*. 2008;13:285–289.
22. Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Mancia G. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. *J Hypertens*. 1998;16:1685–1691.
23. Rizzoni D, Muiesan ML, Salvetti M, Castellano M, Bettoni G, Monteduro C, Corbellini C, Porteri E, Guelfi D, Rosei EA. The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during antihypertensive treatment. *J Hypertens*. 2001;19:703–711.
24. Mancia G, De Backer G, Dominiczak A, et al Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2007;25:1105–1187.
25. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med*. 2010;362:1575–1585.
26. Mann JF, Schmieder RE, McQueen M, et al ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. *Lancet*. 2008;372:547–553.
27. Mancia G, Messerli F, Bakris G, Zhou Q, Champion A, Pepine CJ. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. *Hypertension*. 2007;50:299–305.
28. Verdecchia P, Angeli F, Gattobigio R, Rapicetta C, Reboldi G. Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. *Am J Hypertens*. 2007;20:154–161.
29. Kikuya M, Hozawa A, Ohkubo T, Tsuji I, Michimata M, Matsubara M, Ota M, Nagai K, Araki T, Satoh H, Ito S, Hisamichi S, Imai Y. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. *Hypertension*. 2000;36:901–906.
30. Sander D, Kukla C, Klingelhöfer J, Winbeck K, Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study. *Circulation*. 2000;102:1536–1541.
31. O'Brien E, Asmar R, Beilin L, et al European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. *J Hypertens*. 2003;21:821–848.
32. Hansson L. Antihypertensive treatment: does the J-curve exist? *Cardiovasc Drugs Ther*. 2000;14:367–372.
33. Zanchetti A, Mancia G. Longing for clinical excellence: a critical outlook into the NICE recommendations on hypertension management—is nice always good? *J Hypertens*. 2012;30:660–668.
34. Franklin SS. Ageing and hypertension: the assessment of blood pressure indices in predicting coronary heart disease. *J Hypertens Suppl*. 1999;17:S29–S36.
35. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Pede S, Porcellati C. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. *Hypertension*. 1998;32:983–988.
36. Mancia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. *J Hypertens*. 2004;22:435–445.

Novelty and Significance

What Is New?

- This is a detailed report on the long-term effect of double blockade (angiotensin receptor antagonist + angiotensin converting enzyme inhibitor) of the renin-angiotensin system on ambulatory blood pressure, vis-à-vis the blockade provided by angiotensin receptor antagonist or angiotensin converting enzyme inhibitor only. A thorough description of the relationship between the effect of antihypertensive treatment on clinic and ambulatory blood pressure (BP) is provided, including the quantitative difference between the 2 sets of values at different tightness of clinic BP control.

What Is Relevant?

- The results show that in ONTARGET double blockade of the renin-angiotensin system lowered ambulatory BP more than predictable based on clinic BP data. This rules out the possibility that an insufficient BP reduction was

responsible for the disappointing effect of this treatment strategy on outcome reported in the main study. The results also provide the novel evidence that, whereas clinic BP is markedly greater than ambulatory BP at baseline drug treatment, the difference becomes progressively less (and eventually superimposable) as clinic BP control becomes tighter. This is relevant to the issue of which should be the target ambulatory BP with treatment, on which little or no evidence is available.

Summary

The article provides a detailed description of the ambulatory BP effects of the 3 different treatments used in the ONTARGET. It highlights the limited relationship between these effects and those on clinic BP. It also provides evidence on which may be the ambulatory BP values that correspond with the different target clinic BPs recommended by guidelines for treatment.

Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)

Giuseppe Mancia, Gianfranco Parati, Grzegorz Bilo, Peggy Gao, Robert Fagard, Josep Redon, Istvan Czuriga, Martin Polák, José M. Ribeiro, Ramiro Sanchez, Bruno Trimarco, Paolo Verdecchia, Walter van Mieghem, Koon Teo, Peter Sleight and Salim Yusuf

Hypertension. 2012;60:1400-1406; originally published online October 15, 2012;

doi: 10.1161/HYPERTENSIONAHA.112.199562

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2012 American Heart Association, Inc. All rights reserved.

Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://hyper.ahajournals.org/content/60/6/1400>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Hypertension* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Hypertension* is online at:
<http://hyper.ahajournals.org/subscriptions/>